ArticleEuropean radiology2026
Predicting histopathological growth patterns and prognosis of colorectal liver metastases using MRI.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Liver metastases beyond classical imaging findings.Abdominal radiology (New York) · 2026Review
- Histologic Growth Pattern Assessment in Colorectal Liver Metastases with Photoacoustic Imaging: Exciting Potential for Clinical Applications.Radiology. Imaging cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo identify MR imaging features of replacement histopathological growth patterns (rHGPs) of colorectal liver metastases (CRLMs) distinguishable from those of desmoplastic HGPs (dHGPs) and explore their relationships with prognosis. MATERIALS AND
methodsSeventy-nine patients with 104 CRLMs who underwent gadoxetic acid-enhanced MR followed by partial hepatectomy were included as a derivation cohort. The CRLMs were rHGPs or dHGPs. MR images of the CRLMs, focusing on the tumor and segmented tumor-liver interface zones (peritumoral area), were quantitatively evaluated and statistically analyzed. The statistically significant findings from the derivation cohort were validated in an independent external cohort.
resultsIn the derivation cohort, there were no significant differences among tumor sizes, contrast-to-noise ratios (CNRs), or enhancement ratios (ERs) of the tumors with rHGPs (n = 43) and dHGPs (n = 61) (p > 0.05). The peritumoral area was only identified during the arterial and portal phases. The thickness, CNR, and ER of the peritumoral area on the arterial and portal phase images of the rHGP group were significantly larger than those of the dHGP group (p < 0.05). The area under the ROC curve for predicting rHGP based on CNR during the arterial phase was the highest at 0.920. The peritumoral area CNR during the arterial phase was associated with a poor prognosis (p < 0.05). The usefulness of these parameters was confirmed in the validation cohort (p < 0.05).
conclusionThe CRLMs with rHGPs had thicker peritumoral areas with higher CNR and ER during the arterial phase, and the CNR during the arterial phase was an independent indicator of poor prognosis. KEY POINTS: Question Can MR imaging characteristics predict histopathological growth patterns (HGPs) of colorectal liver metastases (CRLMs), which have been established as independent predictors of prognosis? Findings CRLMs with replacement HGPs showed thicker, more enhanced peritumoral areas with higher contrast ratios than those with desmoplastic HGPs during the arterial phase. Clinical relevance Increased thickness and predominant enhancement of the peritumoral area during the arterial phase may serve as predictive markers for identifying replacement HGPs in CRLMs, which are linked to a poorer prognosis, in contrast to desmoplastic HGPs.
Indexed as
Identifiers
41139172What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.